Vir Biotechnology reported new data showing its combination regimen for chronic hepatitis D maintains low viral levels, reinforcing the therapy’s potential as clinical studies advance. The company said pivotal trials are progressing ahead of schedule following results presented at AASLD25, and positioned the combo regimen as a potential new option in a disease with limited treatments. Vir’s update signals confidence in the program’s regulatory trajectory and commercial prospects if outcomes hold in larger cohorts.